SRNE Sorrento Therapeutics, Inc. gains 45% Oct 18, 2017

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs worldwide. The company's primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. It is developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. The company's preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor-T Cell and Chimeric Antigen Receptor Natural Killer cells for adoptive cellular immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. http://www.priceseries.com/trade/SRNE-Sorrento-Therapeutics-Inc-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2017100420171018.html